药物服务干预对老年高血压患者的治疗及用药安全性的影响

doi:10.3969/j.issn.1000-8535.2023.12.008

摘要/Abstract

摘要： 目的探讨药物服务干预对老年高血压患者的治疗及用药安全性的影响。方法选取2020年6月—2021年12月潮州市中医药研究所门诊部和潮州市中医医院高血压患者90例为研究对象,采用随机数字表法分为观察组45例（给予药物服务干预）,对照组45例（给予常规用药指导）。比较干预后血压控制水平、健康知识认知、治疗依从性、自我管理行为、生活质量及药物不良反应等情况。结果干预后,观察组舒张压、收缩压、不良反应发生率均低于对照组（P<0.05）。干预后,观察组健康知识认知水平、治疗依从率、自我管理行为评分、生活质量评分均高于对照组（P<0.05）。结论采用药物服务干预的方式能够较好控制老年高血压患者血压水平,提升其健康知识认知水平与治疗依从性,改善自我管理行为状况,提高生活质量。

关键词: 药物服务干预, 老年高血压, 用药安全性, 健康知识认知水平, 自我管理行为

Abstract: Objective To investigate the effect of drug service intervention on the treatment and drug safety of elderly patients with hypertension．Methods From June 2020 to December 2021,a total of 90 patients with hypertension from Chaozhou Institute of traditional Chinese Medicine and Chaozhou Hospital of Traditional Chinese Medicine were selected as the study objects,and were divided into observation group（45 cases,given drug service intervention）and control group（45 cases,given routine drug guidance）by random number table method．The blood pressure control level,health knowledge cognition level,treatment compliance,self-management behavior,quality of life and adverse drug reactions of elderly patients with hypertension were compared after intervention．Results After intervention,the incidence of diastolic blood pressure,systolic blood pressure and adverse drug reactions in the observation group were lower（P<0.05）．After intervention,the health knowledge cognition level,treatment compliance rate,self-management behavior score and quality of life score of the observation group were higher（P<0.05）．Conclusions The use of drug service intervention can better control the blood pressure level of elderly patients with hypertension,improve their health knowledge cognition and treatment compliance,improve self-management behavior and improve quality of life．

Key words: drug service intervention, hypertension in the elderly, drug safety, health knowledge cognition level, self-management behavior

邱秀君, 陈越, 冯文才. 药物服务干预对老年高血压患者的治疗及用药安全性的影响[J]. 广州医药, 2023, 54(12): 49-54.

QIU Xiujun, CHEN Yue, FENG Wencai. Influence of drug service intervention on the treatment and drug safety of elderly patients with hypertension[J]. Guangzhou Medical Journal, 2023, 54(12): 49-54.

参考文献

[1] MACKENZIE I S,ROGERS A,POULTER N R,et al.Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK(TIME study):A prospective,randomised,open-label,blinded-endpoint clinical trial[J].Lancet,2022,400(10361):1417-1425.
[2] O'BRIEN M,PAZ-ARES L,MARREAUD S,et al.Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer(PEARLS/KEYNOTE-091):An interim analysis of a randomised,triple-blind,phase 3 trial[J].Lancet Oncol,2022,23(10):1274-1286.
[3] GNANENTHIRAN S R,BORGHI C,BURGER D,et al.Renin-angiotensin system inhibitors in patients with COVID-19:A meta-analysis of randomized controlled trials led by the international society of hypertension[J].J Am Heart Assoc,2022,11(17):e026143.
[4] SUGAWARA S,KONDO M,YOKOYAMA T,et al.Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer:First results from the phase 2 J-ALTA study[J].Int J Clin Oncol,2022,27(12):1828-1838.
[5] SARRAJU A,BAKRIS G,CANNON C P,et al.Cardiovascular effects of canagliflozin in relation to renal function and albuminuria[J].J Am Coll Cardiol,2022,80(18):1721-1731.
[6] 王增武,王文.中国高血压防治指南(2018年修订版)解读[J].中国心血管病研究,2019,17(3):193-197.
[7] 中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.老年高血压的诊断与治疗中国专家共识(2011版)[J].中华内科杂志,2012,51(1):76-82.
[8] JAÏS X,BRENOT P,BOUVAIST H,et al.Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension(RACE):A multicentre,phase 3,open-label,randomised controlled trial and ancillary follow-up study[J].Lancet Respir Med,2022,10(10):961-971.
[9] MICHAEL M,GROOTHOFF J W,SHASHA-LAVSKY H,et al.Lumasiran for advanced primary hyperoxaluria type 1:Phase 3 ILLUMINATE-C trial[J].Am J Kidney Dis,2023,81(2):145-155.
[10] SWEENEY C J,MARTIN A J,STOCKLER M R,et al.Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer(ENZAMET):An international,open-label,randomised,phase 3 trial[J].Lancet Oncol,2023,24(4):323-334.
[11] STRICKLER J H,CERCEK A,SIENA S,et al.Tucatinib plus trastuzumab for chemotherapy-refractory,HER2-positive,RAS wild-type unresectable or metastatic colorectal cancer(MOUNTAINEER):A multicentre,open-label,phase 2 study[J].Lancet Oncol,2023,24(5):496-508.
[12] YONG K,WILSON W,de TUTE R M,et al.Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales(CARDAMON):A randomised,phase 2,non-inferiority trial[J].Lancet Haematol,2023,10(2):e93-e106.
[13] PLATZBECKER U,DELLA PORTA M G,SANTINI V,et al.Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive,transfusion-dependent,lower-risk myelodysplastic syndromes(COMMANDS):Interim analysis of a phase 3,open-label,randomised controlled trial[J].Lancet,2023,402(10399):373-385.
[14] MOUTCHIA J,MCCLELLAND R L,AL-NAAMANI N,et al.Minimal clinically important difference in the 6-minute-walk distance for patients with pulmonary arterial hypertension[J].Am J Respir Crit Care Med,2023,207(8):1070-1079.
[15] MACHADO T R L,de PÁDUA C A M,de MIRANDA DRUMMOND P L,et al.Factors associated with potentially inappropriate medications in elderly with multiple myeloma[J].J Oncol Pharm Pract,2023:10781552231190009.
[16] SONABEND A M,GOULD A,AMIDEI C,et al.Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma:A phase 1 trial[J].Lancet Oncol,2023,24(5):509-522.
[17] MOUSA S I,NYBERG F,HAJIEBRAHIMI M,et al.Initiation of antihypertensive drugs to patients with confirmed COVID-19-A population-based cohort study in Sweden[J].Basic Clin Pharmacol Toxicol,2022,131(3):196-204.
[18] HALLER H,BIANCHI S,MCCAFFERTY K,et al.Safety and efficacy of patiromer in hyperkalemic patients with CKD:A pooled Analysis of three randomized trials[J].Kidney360,2022,3(12):2019-2026.
[19] LIAO C T,TOH H S,SUN L,et al.Cost-effectiveness of intensive vs standard blood pressure control among older patients with hypertension[J].JAMA Netw Open,2023,6(2):e230708.
[20] BARRO M,YAMÉOGO A R,MBA R D,et al.Modelling factors associated with therapeutic inertia in hypertensive patients:Analysis using repeated data from a hospital registry in West Africa[J].Medicine(Baltimore),2022,101(49):e31147.
[21] GUR S,WEIZMAN S,HERMESH H,et al.Comparison of medical treatment of patients with schizophrenia in general practitioners' clinics versus mental health clinics:A cohort study[J].J Psychosom Res,2023(171):111383.